This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
"Given the elevated bleeding risks associated with traditional anticoagulants, particularly when combined with antiplatelet agents, abelacimab may offer a safer alternative for patients with atrialfibrillation,” said Christian T. incidence rate for rivaroxaban to a 3.5% incidence rate for abelacimab 150 mg). [1] vs. 7.7%). [2]
Patients with atrialfibrillation, particularly older patients, are frequently at a high risk of bleeding. Ruff, MD, MPH, senior investigator of TIMI Group, director GeneralCardiology, Brigham and Women's Hospital, and associate professor, Harvard Medical School. in the low risk category to 21.2%
Affecting 60 million people worldwide 1 , the prevalence of atrialfibrillation (AFib) is expected to increase by 60% by 2050 due to an aging population and rising cardiometabolic risk factors 2. In addition, the Centers for Disease Control and Prevention (CDC) estimates that more than 12 million Americans will have AFib by 2030 3.
In an earlier post on Embolic Stroke of Undetermined Source (ESUS) , I had mentioned about ARCADIA trial (AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke) which was testing whether there is role for apixaban compared to aspirin for prevention of recurrent stroke in ESUS. 2023.27188.
Stroke is often due to sudden loss of blood supply to a region of the brain which usually results in paralysis of a part of the body. Stroke could also be due to bleeding into a part of the brain. Strokes and heart disease are linked together in various ways. Stroke can occur after a heart attack as well.
Occasionally there could be an irregular rhythm originating from the upper chambers of the heart known as atrialfibrillation. Atrialfibrillation, known in short as A-FIB causes almost standstill of the upper chambers. If a blood vessel of the brain is blocked, it results in weakness of a side known as stroke.
This condition is known as atrialfibrillation, in which the upper chambers of the heart generate very fast irregular signals but fail to contract well. If these clots migrate to the blood vessels of the brain, a stroke may result. Reduced function of the thyroid gland is also associated with heart disease.
Left ventricular hypertrophy, left atrial enlargement, QRS axis deviation (left more than right), conduction abnormalities like increased P-R interval and bundle branch block may be noted. SAM causes LVOTO, increased ejection time and a decreased stroke volume, as well as mitral regurgitation due to poor coaptation of the leaflets.
Rate vs Rhythm Control in AtrialFibrillation Rate vs rhythm control as a management strategy in atrialfibrillation has been a long standing topic for debate. EAST-AFNET 4 trial had 2789 patients with early atrialfibrillation and cardiovascular conditions [8].
The authors reported that the regular use of fish oil supplements might be a risk factor for atrialfibrillation among general population. In their study healthy stage was considered as primary stage, occurrence of atrialfibrillation as secondary stage, major adverse cardiovascular events tertiary stage and death as end stage.
A potentially serious drug interaction between diltiazem and apixaban or rivaroxaban has been reported in US Medicare patients taking these drugs together for atrialfibrillation. The study compared serious bleeding risk for new users of apixaban or rivaroxaban with atrialfibrillation treated with diltiazem or metoprolol.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content